Prolia(denosumab)
Jubbonti, Prolia, Wyost, Xgeva (denosumab) is an antibody pharmaceutical. Denosumab was first approved as Prolia on 2010-05-26. It is used to treat osteoporotic fractures and postmenopausal osteoporosis in the USA. It has been approved in Europe to treat bone fractures, bone resorption, neoplasm metastasis, and postmenopausal osteoporosis. The pharmaceutical is active against tumor necrosis factor ligand superfamily member 11.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Wyost, Xgeva (discontinued: Xgeva)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| postmenopausal osteoporosis | EFO_0003854 | D015663 | — |
| osteoporotic fractures | — | D058866 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
denosumab, Xgeva, Amgen Inc. | |||
| 2121-12-05 | Orphan excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J0897 | Injection, denosumab, 1 mg |
Clinical
Clinical Trials
321 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteoporosis | D010024 | EFO_0003882 | M81.0 | 3 | 9 | 15 | 6 | 8 | 41 |
| Postmenopausal osteoporosis | D015663 | EFO_0003854 | — | 1 | 3 | 7 | 1 | 4 | 16 |
| Bone neoplasms | D001859 | EFO_0003820 | D16 | — | 4 | 5 | 2 | — | 11 |
| Neoplasms | D009369 | — | C80 | 1 | 3 | 3 | 1 | 1 | 9 |
| Giant cell tumor of bone | D018212 | — | — | — | 3 | — | 2 | — | 5 |
| Giant cell tumors | D005870 | — | — | — | 3 | — | 2 | — | 5 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | — | 2 | — | 1 | — | 3 |
| Bone diseases | D001847 | — | M89.9 | — | — | 1 | 1 | — | 2 |
| Hip osteoarthritis | D015207 | EFO_1000786 | M16 | — | — | — | 1 | — | 1 |
| Hyperparathyroidism | D006961 | EFO_0008506 | E21.3 | — | — | — | 1 | — | 1 |
Show 1 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 9 | 5 | — | — | 15 |
| Metabolic bone diseases | D001851 | — | — | 1 | 5 | 8 | — | — | 14 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | 2 | 8 | — | 1 | 11 |
| Multiple myeloma | D009101 | — | C90.0 | — | 6 | 3 | — | — | 9 |
| Prostatic neoplasms | D011471 | — | C61 | — | — | 8 | — | — | 8 |
| Plasma cell neoplasms | D054219 | — | — | — | 4 | 3 | — | — | 7 |
| Bone marrow diseases | D001855 | — | — | — | 1 | 5 | — | — | 6 |
| Castration-resistant prostatic neoplasms | D064129 | — | — | — | 1 | 4 | — | — | 5 |
| Second primary neoplasms | D016609 | — | — | — | 2 | 2 | — | — | 4 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 2 | 1 | — | — | 3 |
Show 12 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 3 | — | — | — | 3 |
| Melanoma | D008545 | — | — | 1 | 2 | — | — | — | 2 |
| Renal insufficiency | D051437 | — | N19 | 1 | 1 | — | — | — | 2 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | 1 | — | — | — | 2 |
| Arthritis | D001168 | EFO_0005856 | M05-M14 | 1 | 1 | — | — | — | 2 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | 1 | — | — | — | 1 |
| Smoldering multiple myeloma | D000075122 | — | — | — | 1 | — | — | — | 1 |
| Chondrosarcoma | D002813 | — | — | — | 1 | — | — | — | 1 |
| Granuloma | D006099 | — | — | — | 1 | — | — | — | 1 |
| Aneurysmal bone cysts | D017824 | EFO_1001760 | M85.5 | — | 1 | — | — | — | 1 |
Show 24 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Male breast neoplasms | D018567 | — | — | 1 | — | — | — | — | 1 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | — | — | — | — | 1 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Postmenopause | D017698 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteonecrosis | D010020 | EFO_0004259 | M87 | — | — | — | — | 2 | 2 |
| Prostheses and implants | D019736 | — | — | — | — | — | — | 1 | 1 |
| Tooth loss | D016388 | — | — | — | — | — | — | 1 | 1 |
| Anodontia | D000848 | — | K00.0 | — | — | — | — | 1 | 1 |
| Infections | D007239 | EFO_0000544 | — | — | — | — | — | 1 | 1 |
| Communicable diseases | D003141 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Denosumab |
| INN | denosumab |
| Description | Immunoglobulin G2, anti-(human tumor necrosis factor ligand superfamily member 11 (human osteoclast differentiation factor))(human monoclonal AMG162 heavy chain), disulfide with human monoclonal AMG162 light chain, dimer |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1237023 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB06643 |
| UNII ID | 4EQZ6YO2HI (ChemIDplus, GSRS) |
Target
Agency Approved
TNFSF11
TNFSF11
Organism
Homo sapiens
Gene name
TNFSF11
Gene synonyms
OPGL, RANKL, TRANCE
NCBI Gene ID
Protein name
tumor necrosis factor ligand superfamily member 11
Protein synonyms
CD254, ODF, OPGL, Osteoclast differentiation factor, Osteoprotegerin ligand, RANKL, receptor activator of nuclear factor kappa B ligand, Receptor activator of nuclear factor kappa-B ligand, TNF-related activation-induced cytokine, TRANCE, tumor necrosis factor (ligand) superfamily, member 11, tumor necrosis factor ligand 6B, tumor necrosis factor superfamily member 11
Uniprot ID
Mouse ortholog
Tnfsf11 (21943)
tumor necrosis factor ligand superfamily member 11 (Q9R1Y0)
Alternate
No data
Variants
No data
Financial
Estimated US medical usage
Denosumab
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 14,740 documents
View more details
Safety
Black-box Warning
Black-box warning for: Prolia
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
164,421 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use